We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

MDxHealth SA has announced that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.

The presentation, "Epigenetic Biomarkers in Oncology", will highlight the development and commercialization of epigenetic diagnostic tests, several of which are now commercially available and used routinely in clinical practice. 

All cancers show epigenetic changes. Measuring the epigenetic changes associated with specific genes can help guide physicians in the management of a patient's disease.  With continued market adoption of the ConfirmMDx® for Prostate Cancer test, the inclusion of PredictMDx® for Glioblastoma into the NCCN guidelines, and the launch of Cologuard® for colon cancer by licensee Exact Sciences, there are now three successful diagnostic tests on the U.S. market using MDxHealth's epigenetic technology and biomarkers.